



Investor Presentation
August 2025



Our Technology

Sample Preparation Technology

Mining and Manufacturing



Minerals:
Iron ore
Gold
Nickel
Copper
Aluminium
Bauxite
Manganese
Uranium
Lithium
Mineral sands
Commercial labs

Materials:
Cement
Steel
Glass
Ceramics
Research
Education

Raw
Samples



Prepared
Samples

Chemical Analysis



Analysis Techniques:
XRF
ICP
Fire Assay
Photon Assay

Lab Products

Orbis Sample Preparation Products

For mineral analysis labs (XRF, ICP, Fire Assay, Photon Assay)



Laboratory Jaw
Crushers



Smart Splitting
Crushing Systems



Sample Weighing Station

Samples are weighed and the final sample weight is entered into the PLC



Laboratory Crusher

Samples crushed from size of up to 110mm down to <2mm



Sample Splitter

Splitter automatically creates representative sample at required weight for analysis process

Lab Products


Sample Preparation Products

For mineral and material analysis labs (XRF, ICP)

X-Ray Flux




Platinum Labware



Recycling service of turning used platinum products into new items

Fusion Machines



Lab Products

Analytical Instruments

XRTGA 1100

Thermogravimetric Analyser

Used for thermal analysis of moisture, volatiles, ash, fixed carbon or loss on ignition

Used in existing mining / construction material industries and new markets such as production quality control of food, plastics and agricultural products

Provides complementary data for the XRF analysis process in materials such as iron ore and cement



Lab Products


Analytical Instruments

AS Series pH and EC Robots

Used for pH and electrical conductivity testing in liquid and solid samples.

Testing application examples:

- Soil and environmental
- Beverages (beer, wine)
- Drinking water
- Water purification processes
- Waste water treatment plants




CS1232 Carbon Sulphur Analyser

Used for elemental analysis of carbon and sulphur in samples.

Testing application examples:

- Mining: gold, copper, bauxite, graphite
- Thermal and coking coal (mining, power plants, steel plants)
- Cement plants
- Agricultural soils and plants

Laboratory Products Flowchart





FY25 Highlights



- Record profit
- Strong demand from mining and industrial customers
- International sales growth in numerous developing markets
- Installed base of machines is generating additional recurring revenue in the form of consumable sales and platinum labware recycling
- Acquired the remaining 50% of Orbis Mining on 26 July 2024 for upfront consideration of \$3.91m
- Acquired 100% of Labfit on 13 December 2024 for upfront consideration of \$1.16m

FY25 Financial Highlights

- Revenue down 1% to \$59.5m vs FY24
- NPAT up 17% to \$10.4m vs FY24
- \$10.1m positive operating cashflow
- 7.4 cents Earnings Per Share
- Fully franked dividend of 4.5 cents per share
- Record quarterly profit before tax of \$4.3m from revenue of \$16.8m during June Q4, driven by strong consumable and Orbis crusher sales, and growth in international sales



Balance Sheet

(\$m)	2025	2024	Change
Cash and cash equivalents	12.2	12.0	2%
Trade and other receivables	10.3	9.6	8%
Inventories	18.8	17.0	11%
Other assets	0.6	0.6	1%
Property, plant and equipment	10.1	9.1	10%
PPE lease asset	1.7	1.7	(1%)
Intangible assets	17.3	16.6	4%
Deferred tax asset	1.8	1.6	15%
Total assets	72.8	68.2	7%
Trade and payables			
- platinum loan provisions	0.7	1.3	(44%)
- other items	7.1	6.0	19%
Debt (short-term)	0.2	1.6	(89%)
Debt (long-term)	0.9	0.0	100%
Current lease liabilities	0.8	0.6	28%
Non-current lease liabilities	1.0	1.1	(15%)
Income tax liability	0.9	1.1	(12%)
Deferred tax liability	1.0	1.0	2%
Total liabilities	12.6	12.7	(1%)
Total equity	60.2	55.5	8%

- Net cash position of \$11.1m
- \$0.9m debt for our Melbourne platinum factory has been reclassified as long-term, with a new three-year term finalised
- Orbis acquisition recorded directly to equity as transaction was with non-controlling interest, which reduced net assets
- Platinum metal inventory loans reduced due to current high cost of interest. Reduced to nil in July 2025

Cash Flow Statements

(\$m)	2025	2024
Net cash inflow from operating activities	10.1	8.1
Net cash (outflow) from investing activities	(2.2)	(1.6)
Net cash (outflow) from financing activities	(7.7)	(4.8)
Cash at start of period	12.0	10.4
Net increase in cash	0.2	1.6
Cash at end of period	12.2	12.0

Highlights:

- Acquisitions:
 - Orbis \$1.9m classified as financing activities as transaction was with non-controlling interest
 - Labfit \$1.0m classified as investing activities
- Financing activities: \$4.1m cash paid out for FY24 dividend (FY23 dividend: \$3.6m)


Consumables

Laboratory consumables and chemicals



(\$m)	FY25	FY24	FY23
Sales revenue	19.3	18.8	16.9
Change in % *	2%	11%	40%
NPBT	7.2	5.7	5.2
Change in % *	26%	9%	27%
Margin %	38%	30%	31%

* Compared to immediately prior period



Overview for FY25:

- Revenue up 2% on FY24
- NPBT up 26% on FY24
- Continued robust demand from the mining sector driven by production and exploration
- Record product volumes during FY25, without any substantial increase to our fixed cost base
- Profit and margin increases driven by international sales growth in numerous developing markets
- Key production input lithium compounds reduced in price, reducing selling prices and production costs. Profit per unit sold remaining steady


Precious Metals

Platinum laboratory and industrial products



(\$m)	FY25	FY24	FY23
Sales revenue	21.5	21.5	21.7
Change in % *	0%	(1%)	18%
NPBT	3.5	3.6	3.6
Change in % *	(1%)	0%	27%
Margin %	16%	17%	17%

* Compared to immediately prior period



Overview for FY25:

- Revenue** flat on FY24
- NPBT down 1% on FY24
- Strong demand for both new product and recycling sales
- Recurring orders from mining customers, as increased sample testing requires regular recycling of spent platinum labware products
- Revenue diversification increased, with less concentration of large new metal orders that occurred in prior periods

** Revenue is impacted each period by precious metals prices and product sales mix (precious metals vs fabrication revenue)


Capital Equipment

Laboratory instruments and machines



(\$m)	FY25	FY24	FY23
Sales revenue	22.6	21.8	18.8
Change in % *	4%	16%	75%
NPBT	4.1	4.6	3.4
Change in % *	(11%)	35%	198%
Margin %	18%	21%	18%

* Compared to immediately prior period



Overview for FY25:

- Revenue up 4% on FY24
- NPBT down 11% on FY24
- Strong machines sales globally. Incoming new orders for xrFuse at a lower but normalised run rate. Other product lines either steady or growing
- Orbis NPBT increased by 39% to \$2.4m. Revenue up 20% on FY24 to \$7m. Sales driven by customers in Australia, USA and Canada, predominantly in the gold sector
- xrTGA progressing well with key reference sales achieved
- Labfit fully integrated into main Perth machines factory
- Numerous machines in advanced stages of product development, for release through FY26

Note: Segment results reporting includes 100% of the Revenue and NPBT from Orbis Mining Pty Ltd

Growth Strategy for FY26



- Ramp-up sales strategy on xrTGA
- Grow Orbis laboratory crusher sales in mining markets globally
- Increase Labfit product sales, leveraging our global sales network
- Continue with geographical expansion initiatives
- New product releases:
 - Next generation product upgrades
 - Different size machines or new complementary products
 - Brand-new product ranges
- Expand our portfolio of gold sector analysis products (M&A and internal product developments)
- Continue to pursue M&A opportunities. Our targets are complementary laboratory product manufacturing or supply companies

Corporate Overview

Shareholder Wealth

	EBIT	Earnings Per Share	Dividends Declared Per Share	Share Price	Market Capitalisation
Financial Year	\$	Cents	Cents	\$	\$
2019/20	4,602,319	2.3	1.4	0.24	32,118,193
2020/21	6,818,111	3.8	2.0	0.47	63,916,519
2021/22	8,259,768	4.5	2.5	0.57	77,458,468
2022/23	11,924,806	5.6	3.3	1.17	160,348,236
2023/24	13,470,188	6.4	3.9	1.34	185,757,109
2024/25	14,584,958	7.4	4.5	1.84	258,586,383

Directors

Fred Grimwade – Chairman
 Vance Stazzonelli – Managing Director
 David Brown – Non-Executive Director
 David Kiggins – Non-Executive Director

Shareholders

Board and Management – 12.8%
 Top 20 – 49.1%

Substantial Shareholders

David Brown & Glenys Dawn Brown – 6.6%
 Michael Karl Korber – 6.1%

Capital Structure

Ordinary shares on issue: 140,536,078
 Performance rights: 2,735,934
 Options: Nil

DRP

Please visit www.xrfscientific.com for a copy of the Dividend Reinvestment Plan

Locations

Head Office – Perth
 Manufacturing – Perth and Melbourne
 International Sales/Service – Brussels (Belgium),
 Karlstein (Germany) and Montreal (Canada)

Contact Information

Tel: (08) 9244 0600
86 Guthrie Street, Osborne Park WA

Vance Stazzonelli – CEO
vance@xrfscientific.com

Disclaimer

No responsibility for contents of Investor Presentation

- To the maximum extent permitted by law, XRF Scientific Limited and representatives:
- make no representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient;
- accept no responsibility or liability as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; and
- accept no responsibility for any errors or omissions from this Investor Presentation whether arising out of negligence or otherwise.

Accuracy of projections and forecasts

- This Investor Presentation includes certain statements, opinions, estimates, projections and forward-looking statements with respect to the expected future performance of XRF Scientific Limited. These statements are based on, and are made subject to, certain assumptions which may not prove to be correct or appropriate. Actual results may be materially affected by changes in economic and other circumstances which may be beyond the control of XRF Scientific Limited. Except to the extent implied by law, no representations or warranties are made by XRF Scientific Limited, its advisers or representatives as to the validity, certainty or completeness of any of the assumptions or the accuracy or completeness of the forward-looking statements or that any such statement should or will be achieved. The forward-looking statements should not be relied on as an indication of future value or for any other purpose.

No offer to sell or invitation to buy

- This Investor Presentation does not, and should not be considered to, constitute or form part of any offer to sell, or solicitation of an offer to buy, any shares in XRF Scientific Limited, and no part of this Investor Presentation forms the basis of any contract or commitment whatsoever with any person.

This Investor Presentation does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not permitted under applicable law. Distribution of this Investor Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients must inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Neither XRF Scientific Limited, its advisers or representatives accept any liability to any person in relation to the distribution or possession of this Investor Presentation from or in any jurisdiction.